TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma

To identify drivers of sensitivity and resistance to Protein Arginine Methyltransferase 5 (PRMT5) inhibition, we perform a genome-wide CRISPR/Cas9 screen. We identify TP53 and RNA-binding protein MUSASHI2 (MSI2) as the top-ranked sensitizer and driver of resistance to specific PRMT5i, GSK-591, respe...

Descripción completa

Detalles Bibliográficos
Autores principales: Erazo, Tatiana, Evans, Chiara M., Zakheim, Daniel, Chu, Karen L., Refermat, Alice Yunsi, Asgari, Zahra, Yang, Xuejing, Da Silva Ferreira, Mariana, Mehta, Sanjoy, Russo, Marco Vincenzo, Knezevic, Andrea, Zhang, Xi-Ping, Chen, Zhengming, Fennell, Myles, Garippa, Ralph, Seshan, Venkatraman, de Stanchina, Elisa, Barbash, Olena, Batlevi, Connie Lee, Leslie, Christina S., Melnick, Ari M., Younes, Anas, Kharas, Michael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515221/
https://www.ncbi.nlm.nih.gov/pubmed/36167829
http://dx.doi.org/10.1038/s41467-022-33137-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515221/
https://www.ncbi.nlm.nih.gov/pubmed/36167829
http://dx.doi.org/10.1038/s41467-022-33137-8

Ejemplares similares